{
  "main_header": {
    "sid": 476646,
    "name": "Alpa Laboratorie",
    "stock_name": "Alpa Laboratorie",
    "full_name": "Alpa Laboratories Ltd",
    "name_url": "stocks-analysis/alpa-laboratorie",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "105.60",
    "chg": 4.05,
    "chgp": "3.99%",
    "dir": 1,
    "prev_price": "101.55",
    "mcapval": "222.19 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532878,
    "symbol": "ALPA",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE385I01010",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "23:51 PM",
    "bse_nse_vol": "14.89 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alpa-laboratorie-476646-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Alpa Laboratories Adjusts Valuation Grade, Signaling Competitive Position in Pharmaceuticals Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alpa-laboratories-valuation-grade-downgraded-from-very-attractive-to-attractive-1494275",
        "imagepath": "",
        "date": "2025-03-20 08:00:19",
        "description": "Alpa Laboratories has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company, classified as a microcap, has reported a price-to-earnings (PE) ratio of 9.38 and a price-to-book value of 1.44. Its enterprise value to EBITDA stands at 16.03, while the enterprise value to EBIT is noted at 21.80. The PEG ratio is particularly noteworthy at 0.23, indicating a favorable growth perspective relative to its earnings.\n\nIn terms of performance, Alpa Laboratories has shown resilience with a one-year stock return of 28.22%, significantly outperforming the Sensex, which returned 4.77% over the same period. Over a five-year horizon, the company has delivered an impressive return of 806.85%, compared to the Sensex's 166.72%.\n\nWhen compared to its peers, Alpa Laboratories maintains a competitive edge with a lower PE ratio than several companies in the s..."
      },
      {
        "title": "Alpa Laboratories Adjusts Valuation Grade Amid Strong Financial Metrics and Competitive Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alpa-laboratories-valuation-grade-upgraded-from-attractive-to-very-attractive-1106607",
        "imagepath": "",
        "date": "2025-02-24 12:56:51",
        "description": "Alpa Laboratories has recently undergone a valuation adjustment, reflecting its strong financial metrics within the pharmaceuticals and drugs industry. The company boasts a price-to-earnings (PE) ratio of 9.14 and a price-to-book value of 1.40, indicating a favorable valuation compared to its peers. Additionally, Alpa's enterprise value to EBITDA stands at 15.30, while its enterprise value to EBIT is recorded at 20.81.\n\nThe company's return on capital employed (ROCE) is 13.05%, and its return on equity (ROE) is 12.65%, showcasing solid profitability. In comparison to its industry peers, Alpa Laboratories presents a more attractive valuation profile, particularly when considering its PEG ratio of 0.22, which is significantly lower than that of competitors like Shree Ganesh Rem and Shukra Pharma, which have higher PE ratios and EV to EBITDA metrics.\n\nDespite recent stock performance showing a decline over the..."
      },
      {
        "title": "Alpa Laboratories Reports Mixed Financial Results with Record Profit After Tax in December 2024",
        "link": "https://www.marketsmojo.com/news/result-analysis/alpa-laboratories-reports-december-2024-pat-of-rs-8-90-crore-up-71-year-on-year-1010944",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/AlpaLaboratorie_quaterlyResult_446142.png",
        "date": "2025-02-14 11:44:45",
        "description": "Alpa Laboratories has announced its financial results for the quarter ending December 2024, showcasing a significant increase in Profit After Tax (PAT) to Rs 8.90 crore, the highest in five quarters. However, challenges persist with a notable decline in Profit Before Tax and concerns regarding income sustainability and liquidity."
      }
    ],
    "total": 22,
    "sid": "476646",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/alpa-laboratories-476646"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "The Trading Window shall remain closed with effect from 1st April 2025 till 48 hours after the declaration of Financial Results of the Company for the fourth quarter and financial year ending 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Clarification On The Format Prescribed By SEBI For The Financial Results.",
      "datetime": "18-Mar-2025",
      "details": "Clarification on the format prescribed by SEBI for the Financial Results.",
      "source": "BSE"
    },
    {
      "caption": "Integrated Filing (Financial)",
      "datetime": "17-Feb-2025",
      "details": "Integrated Filing (Financial) for the Quarter and nine months ended December 31 2024",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Alpa Laboratories Adjusts Valuation Grade, Signaling Competitive Position in Pharmaceuticals Sector

2025-03-20 08:00:19

Alpa Laboratories has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company, classified as a microcap, has reported a price-to-earnings (PE) ratio of 9.38 and a price-to-book value of 1.44. Its enterprise value to EBITDA stands at 16.03, while the enterprise value to EBIT is noted at 21.80. The PEG ratio is particularly noteworthy at 0.23, indicating a favorable growth perspective relative to its earnings. In terms of performance, Alpa Laboratories has shown resilience with a one-year stock return of 28.22%, significantly outperforming the Sensex, which returned 4.77% over the same period. Over a five-year horizon, the company has delivered an impressive return of 806.85%, compared to the Sensex's 166.72%. When compared to its peers, Alpa Laboratories maintains a competitive edge with a lower PE ratio than several companies in the s...

Read More

Alpa Laboratories Adjusts Valuation Grade Amid Strong Financial Metrics and Competitive Positioning

2025-02-24 12:56:51

Alpa Laboratories has recently undergone a valuation adjustment, reflecting its strong financial metrics within the pharmaceuticals and drugs industry. The company boasts a price-to-earnings (PE) ratio of 9.14 and a price-to-book value of 1.40, indicating a favorable valuation compared to its peers. Additionally, Alpa's enterprise value to EBITDA stands at 15.30, while its enterprise value to EBIT is recorded at 20.81. The company's return on capital employed (ROCE) is 13.05%, and its return on equity (ROE) is 12.65%, showcasing solid profitability. In comparison to its industry peers, Alpa Laboratories presents a more attractive valuation profile, particularly when considering its PEG ratio of 0.22, which is significantly lower than that of competitors like Shree Ganesh Rem and Shukra Pharma, which have higher PE ratios and EV to EBITDA metrics. Despite recent stock performance showing a decline over the...

Read More

Alpa Laboratories Reports Mixed Financial Results with Record Profit After Tax in December 2024

2025-02-14 11:44:45

Alpa Laboratories has announced its financial results for the quarter ending December 2024, showcasing a significant increase in Profit After Tax (PAT) to Rs 8.90 crore, the highest in five quarters. However, challenges persist with a notable decline in Profit Before Tax and concerns regarding income sustainability and liquidity.

Read More

View All News